<DOC>
	<DOCNO>NCT02507375</DOCNO>
	<brief_summary>This study ass safety tolerability , make preliminary assessment activity , combination pertuzumab erlotinib patient locally advanced metastatic non-small cell lung cancer ( NSCLC ) fail least one prior chemotherapy regimen . The anticipated time study treatment disease progression unacceptable toxicity , target sample size le 100 individual .</brief_summary>
	<brief_title>A Study Pertuzumab With Erlotinib Patients With Locally Advanced Metastatic Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Adult patient great equal 18 year age Histological confirmation nonsmall cell lung cancer ( NSCLC ) Locally advance metastatic disease Failure least one prior regimen standard chemotherapy locally advance metastatic disease Life expectancy equal 12 week Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Baseline Left Ventricular Ejection Fraction ( LVEF ) great equal 50 % A negative pregnancy test one week prior treatment willingness use contraception among woman childbearing potential Availability histological FormalinFixed , ParaffinEmbedded ( FFPE ) tumor tissue Prior chemotherapy , radiotherapy immunotherapy within 4 week study Day 8 Prior treatment agent target growth factor receptors Patients recover acute reversible effect chemotherapy radiotherapy History clinically significant cardiovascular disease History evidence central nervous system metastases Treatment investigational drug within 28 day start study ( day 8 ) Prior cumulative doxorubicin dose 360 mg/m2 equivalent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Non-Squamous</keyword>
</DOC>